Weiss Multi-Strategy Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-19,947	Closed	-$241K	–	621
2020 Q2	$241K	Buy	19,947 +686	+4%	+$7.29K	0.01%	504
2020 Q1	$147K	Sell	19,261 -739	-4%	-$9.97K	0.01%	396
2019 Q4	$356K	Sell	20,000 -34,000	-63%	-$444K	0.01%	552
2019 Q3	$626K	Hold	54,000	–	–	0.01%	477
2019 Q2	$1.2M	Hold	54,000	–	–	0.03%	362
2019 Q1	$1.54M	Buy	54,000 +13,000	+32%	+$282K	0.04%	358
2018 Q4	$810K	Buy	41,000 +1,000	+3%	+$20.1K	0.03%	315
2018 Q3	$884K	Buy	+40,000	New	+$541K	0.02%	412

Other funds holding KALV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Weiss Multi-Strategy Advisers's KALV Position: Q3 2020 in Review

Weiss Multi-Strategy Advisers sold out of KalVista Pharmaceuticals (KALV) in Q3 2020, closing a stake of 19,947 shares — an estimated $241K sold.

Weiss Multi-Strategy Advisers first reported a position in KALV in Q3 2018 and held it in 8 quarters. The position peaked at $1.54M in Q1 2019. 63 funds tracked by Wall St. Rank hold KALV as of Q3 2020.

Weiss Multi-Strategy Advisers reported no remaining KalVista Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 19,947 KalVista Pharmaceuticals shares in Q3 2020, an estimated $241K.
Weiss Multi-Strategy Advisers first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Weiss Multi-Strategy Advisers's KalVista Pharmaceuticals position peaked at $1.54M in Q1 2019.
63 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2020.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2020, filed 16 Nov 2020.